Hunting a cure, Ex-Novartis exec Bastiano Sanna takes the reins at Cambridge diabetes startup Semma
A startup trying to develop a stem cell cure for type 1 diabetes has recruited former Magenta executive Bastiano Sanna — a guy best known for leading the development of Novartis’ cell-based medicines — to serve as the company’s new CEO.
Cambridge-based Semma Therapeutics is bringing Sanna in to replace its interim CEO Elizabeth Stoner. Sanna comes directly from Magenta (another startup developing stem cell tech), where he was chief operating officer. Before that, Sanna was an executive at Novartis’ cell and gene therapy division, overseeing the development of CAR-T drugs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.